Meitheal Pharmaceuticals (Meitheal) is pleased to announce that we have launched Dacarbazine for Injection, USP 200 mg per vial, in a pack of 10 single-dose vials.
ABOUT DACARBAZINE FOR INJECTION, USP
Dacarbazine for Injection is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection is also indicated for Hodgkin’s disease as a secondary line therapy when used in combination with other effective agents.
For full prescribing information, please click on the following link.
Learn more about Dacarbazine for Injection, USP
